BP (BP) shares have done nicely since my last update in October 2020, gaining over 60% from what was then a 25-year low point. Though a welcome rebound, a couple of things still appear to weigh on the stock, the first of which is the lingering impact of last year’s…

I’m sure that Terry Smith and the Fundsmith Equity Fund are well known amongst readers. Ironically I haven’t covered that fund here yet, but it’s not hard to see why it is so popular because Smith takes a very simple approach to investing: buy firms that post stable, high quality…

In a way, Standard Chartered (STAN) sums up the problem with bank stocks. I say that because on paper it looks like a very good long-term proposition. The bank is largely an Asian and emerging market player for one, while it also generates the lion’s share of its income from…

The first quarter really seems to have flown by. It definitely doesn’t feel like three months have passed since the last Micro Portfolio update. Anyway, equities seemed to have posted a pretty good start to the year, with the FTSE All Share Total Return Index scraping out 3.9% in the…

Despite its issues, healthcare giant GlaxoSmithKline (GSK) remains one of the highest quality businesses on the London Stock Exchange. The Glaxo empire, which spans various patented drugs, vaccines and a consumer health segment that owns brands like Sensodyne toothpaste, has generated in excess of £16b worth of free cash flow…